Inari Medical Inc
NASDAQ:NARI
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Inari Medical Inc
NASDAQ:NARI
|
4.7B USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
187.6B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
167.7B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
128.8B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
111.8B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
102.5B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
43.9B EUR |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
45.4B USD |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.7B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
33.6B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Inari Medical Inc
Glance View
Inari Medical Inc., nestled in the heart of Irvine, California, embarked on a mission to revolutionize the treatment for venous diseases with a sense of urgency and ingenuity. Founded in 2011, this medical device company has become a beacon of innovation in the healthcare sector, relentlessly focused on addressing the unmet needs in the treatment of venous thromboembolism (VTE) conditions, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). These life-threatening conditions impact millions globally, presenting a critical challenge that Inari aims to tackle head-on. Their pioneering spirit is showcased in their flagship devices—the FlowTriever and ClotTriever—designed to remove large clots with less risk compared to traditional, invasive surgical methods. By providing minimally invasive mechanical thrombectomy devices, Inari Medical has streamlined treatments to improve patient outcomes, ultimately reducing the burden on healthcare systems. Revenue streams at Inari are intrinsically tied to their innovative products, which are integral in modern therapeutic strategies for clot removal. The commercial success of FlowTriever and ClotTriever is driven by their effectiveness and safety profile, appealing to hospitals and medical professionals looking for advanced solutions to treat VTE. Inari's business model thrives on the sales and adoption of these devices, supported by robust clinical evidence that underpins their efficacy. With a blend of aggressive research and development, education programs for physicians, and a strategic global market expansion, Inari Medical is poised to continue growing in the med-tech sector. Their commitment to addressing large medical needs with cutting-edge solutions not only defines their financial blueprint but also underscores their dedication to transforming patient care across the globe.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Inari Medical Inc is 86.8%, which is below its 3-year median of 87.8%.
Over the last 3 years, Inari Medical Inc’s Gross Margin has decreased from 91.7% to 86.8%. During this period, it reached a low of 86.8% on Sep 30, 2024 and a high of 91.7% on Sep 30, 2021.